| Name | Elara Caring |
|---|---|
| Location | 74 State Road, Unit 103, Kittery, Maine |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 207080 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 3901, 3902, 3903, 3904, 3905, 3906, 3907, 3908, 3909, 4001, 4002, 4005, 4009, 4013, 4027, 4032, 4041, 4043, 4046, 4047, 4062, 4068, 4070, 4073, 4074, 4076, 4083, 4087, 4090, 4092, 4095, 4102, 4103 |
| Quality Rating: |
News Archive
Teaching kids about drugs, alcohol and sex appears to be less controversial than ever before with the majority of parents in a new poll saying schools should and do teach these subjects.
A bacterium that harvests far-red light by making a rare form of chlorophyll (chlorophyll d) has revealed its genetic secrets, according to a team of researchers who recently sequenced the bacteria's genome.
States made little progress in improving health care access, quality, and outcomes and lowering costs in the five years preceding implementation of the major coverage provisions of the Affordable Care Act (2007-2012), according to the Commonwealth Fund's third state health system scorecard. The majority of states declined or failed to improve on two-thirds of the 34 scorecard indicators that could be tracked over time.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 97.9 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 100 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 100 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 85.5 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 92.3 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 96.4 | 96.4 |
News Archive
Teaching kids about drugs, alcohol and sex appears to be less controversial than ever before with the majority of parents in a new poll saying schools should and do teach these subjects.
A bacterium that harvests far-red light by making a rare form of chlorophyll (chlorophyll d) has revealed its genetic secrets, according to a team of researchers who recently sequenced the bacteria's genome.
States made little progress in improving health care access, quality, and outcomes and lowering costs in the five years preceding implementation of the major coverage provisions of the Affordable Care Act (2007-2012), according to the Commonwealth Fund's third state health system scorecard. The majority of states declined or failed to improve on two-thirds of the 34 scorecard indicators that could be tracked over time.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 85.3 | 79.6 |
| How often patients got better at getting in and out of bed | 83.6 | 81.1 |
| How often patients got better at bathing | 91.8 | 82.3 |
| How often patients’ breathing improved | 86.3 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 72.7 | 75 |
| How often home health patients had to be admitted to the hospital | 16.4 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 20.9 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 97.9 | 94 |
News Archive
Teaching kids about drugs, alcohol and sex appears to be less controversial than ever before with the majority of parents in a new poll saying schools should and do teach these subjects.
A bacterium that harvests far-red light by making a rare form of chlorophyll (chlorophyll d) has revealed its genetic secrets, according to a team of researchers who recently sequenced the bacteria's genome.
States made little progress in improving health care access, quality, and outcomes and lowering costs in the five years preceding implementation of the major coverage provisions of the Affordable Care Act (2007-2012), according to the Commonwealth Fund's third state health system scorecard. The majority of states declined or failed to improve on two-thirds of the 34 scorecard indicators that could be tracked over time.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.
› Verified 6 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | Not Available |
| Health team communicated well with them | Not Available |
| Health team discussed medicines, pain, and home safety | Not Available |
| How patients rated overall care from agency | Not Available |
News Archive
Teaching kids about drugs, alcohol and sex appears to be less controversial than ever before with the majority of parents in a new poll saying schools should and do teach these subjects.
A bacterium that harvests far-red light by making a rare form of chlorophyll (chlorophyll d) has revealed its genetic secrets, according to a team of researchers who recently sequenced the bacteria's genome.
States made little progress in improving health care access, quality, and outcomes and lowering costs in the five years preceding implementation of the major coverage provisions of the Affordable Care Act (2007-2012), according to the Commonwealth Fund's third state health system scorecard. The majority of states declined or failed to improve on two-thirds of the 34 scorecard indicators that could be tracked over time.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.
› Verified 6 days ago
The patient survey data of Elara Caring is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 80 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 84 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 69 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 86 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 90 | 78 |
News Archive
Teaching kids about drugs, alcohol and sex appears to be less controversial than ever before with the majority of parents in a new poll saying schools should and do teach these subjects.
A bacterium that harvests far-red light by making a rare form of chlorophyll (chlorophyll d) has revealed its genetic secrets, according to a team of researchers who recently sequenced the bacteria's genome.
States made little progress in improving health care access, quality, and outcomes and lowering costs in the five years preceding implementation of the major coverage provisions of the Affordable Care Act (2007-2012), according to the Commonwealth Fund's third state health system scorecard. The majority of states declined or failed to improve on two-thirds of the 34 scorecard indicators that could be tracked over time.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.
› Verified 6 days ago